HK1067645A1 - Tumor antigen peptides originating in cyclophilin b - Google Patents

Tumor antigen peptides originating in cyclophilin b

Info

Publication number
HK1067645A1
HK1067645A1 HK04109605A HK04109605A HK1067645A1 HK 1067645 A1 HK1067645 A1 HK 1067645A1 HK 04109605 A HK04109605 A HK 04109605A HK 04109605 A HK04109605 A HK 04109605A HK 1067645 A1 HK1067645 A1 HK 1067645A1
Authority
HK
Hong Kong
Prior art keywords
tumor antigen
antigen peptides
cyclophilins
cyclophilin
derivatives
Prior art date
Application number
HK04109605A
Other languages
English (en)
Inventor
Kyogo Itoh
Shinya Gomi
Original Assignee
Kyogo Itoh
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyogo Itoh, Dainippon Sumitomo Pharma Co filed Critical Kyogo Itoh
Publication of HK1067645A1 publication Critical patent/HK1067645A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
HK04109605A 1998-06-25 2004-12-03 Tumor antigen peptides originating in cyclophilin b HK1067645A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17844998 1998-06-25
PCT/JP1999/003360 WO1999067288A1 (fr) 1998-06-25 1999-06-24 Peptides d'antigenes tumoraux provenant de la cyclophiline b

Publications (1)

Publication Number Publication Date
HK1067645A1 true HK1067645A1 (en) 2005-04-15

Family

ID=16048723

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109605A HK1067645A1 (en) 1998-06-25 2004-12-03 Tumor antigen peptides originating in cyclophilin b

Country Status (15)

Country Link
US (2) US7041297B1 (fr)
EP (1) EP1090924B8 (fr)
JP (1) JP4413429B2 (fr)
KR (1) KR100653590B1 (fr)
CN (1) CN1318447C (fr)
AT (1) ATE375362T1 (fr)
AU (1) AU749544B2 (fr)
CA (1) CA2331761A1 (fr)
DE (1) DE69937294T2 (fr)
ES (1) ES2294844T3 (fr)
HK (1) HK1067645A1 (fr)
ID (1) ID27788A (fr)
NZ (1) NZ508996A (fr)
TW (1) TWI228128B (fr)
WO (1) WO1999067288A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105306B1 (en) * 2000-08-10 2006-09-12 Trustees Of The University Of Pennsylvania Methods and compositions for modulating somatolactogenic functions
ATE298243T1 (de) * 1999-09-10 2005-07-15 Max Planck Gesellschaft Ant-1 als therapeutisches zielmolekül
WO2001052858A1 (fr) * 2000-01-24 2001-07-26 Trustees Of Tufts College Composes de tetracycline pour le traitement de troubles afferents au cryptosporidium parvum
US6642270B2 (en) * 2000-05-15 2003-11-04 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
US20020128238A1 (en) * 2000-06-16 2002-09-12 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
WO2003055441A2 (fr) * 2001-08-02 2003-07-10 Paratek Pharmaceuticals, Inc. Medicaments
EP2267022B1 (fr) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. Peptides KDR et vaccins les comportant
US20080254445A1 (en) * 2003-09-22 2008-10-16 Kyogo Itoh Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent
TWI261038B (en) * 2004-08-11 2006-09-01 Bo-Cheng Chen Bicycle gear-shifting handgrip
CA2585418A1 (fr) * 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines et procedes d'utilisation
EP2020417A4 (fr) 2006-05-01 2010-10-20 Hitachi Chemical Co Ltd Peptide partiel de la prostasine et anticorps anti-prostasine
WO2008045507A2 (fr) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Composés de tétracycline substitués utilisés pour le traitement d'infections à bacillus anthracis
JP2010512730A (ja) 2006-12-13 2010-04-30 オンコセラピー・サイエンス株式会社 肺癌の腫瘍マーカーおよび治療標的としてのttk
CA2678432A1 (fr) 2007-02-16 2008-08-21 Oncotherapy Science, Inc. Therapie de vaccins destinee a la neovascularisation choroidienne
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
CA2697517A1 (fr) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Genes se rapportant au cancer, cdca5, epha7, stk31 et wdhd1
KR101512885B1 (ko) 2007-09-18 2015-04-16 가부시키가이샤 그린 펩티드 Ctl 유도제 조성물
DK2225253T3 (da) 2007-11-29 2012-08-27 Actelion Pharmaceuticals Ltd Phosphonsyrederivater og deres anvendelse som p2y12- receptorantagonister
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1抗原決定位胜肽及含此胜肽的疫苗
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1胜肽以及含此胜肽之疫苗
DK2408913T3 (en) 2009-03-18 2017-03-06 Oncotherapy Science Inc NEIL3 PEPTIDES AND VACCINES CONTAINING THESE
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Cdc45l胜肽與含此胜肽之疫苗
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
WO2011111392A1 (fr) 2010-03-11 2011-09-15 Oncotherapy Science, Inc. Peptides hjurp et vaccins les comprenant
EP2738255B1 (fr) 2011-07-29 2016-11-23 Tokushima University Peptide issu de erap1 et son utilisation
WO2013024582A1 (fr) 2011-08-12 2013-02-21 Oncotherapy Science, Inc. Peptides mphosph1 et vaccins les contenant
US9427461B2 (en) 2011-10-28 2016-08-30 Oncotherapy Science, Inc. TOPK peptides and vaccines including the same
EP2872531A4 (fr) 2012-07-10 2016-04-06 Oncotherapy Science Inc Peptides épitopes du ly6k pour cellules th1 et vaccins les contenant
US9561265B2 (en) 2012-07-10 2017-02-07 Oncotherapy Science, Inc. KIF20A epitope peptides for TH1 cells and vaccines containing the same
RU2663350C2 (ru) 2012-09-11 2018-08-03 Онкотерапи Сайенс, Инк. Пептиды ube2t и содержащие их вакцины
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2胜肽及含此胜肽之疫苗
TWI651094B (zh) 2013-10-21 2019-02-21 日商大鵬藥品工業股份有限公司 新穎ctl抗原決定部位4連結肽
CN106795204B (zh) 2014-08-04 2021-09-28 肿瘤疗法科学股份有限公司 Urlc10衍生的肽和含有它们的疫苗
KR20220155610A (ko) 2014-08-04 2022-11-23 온코세라피 사이언스 가부시키가이샤 Koc1-유래 펩티드 및 이를 포함하는 백신
CA2956132A1 (fr) 2014-08-04 2016-02-11 Oncotherapy Science, Inc. Peptide derive de cdca1 et vaccin le contenant
KR20180056778A (ko) 2015-10-08 2018-05-29 온코세라피 사이언스 가부시키가이샤 Foxm1 유래 펩티드 및 이를 포함하는 백신
JP6716801B2 (ja) 2018-06-29 2020-07-01 大鵬薬品工業株式会社 抗腫瘍剤及びその評価方法
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
WO2020111167A1 (fr) 2018-11-30 2020-06-04 国立大学法人徳島大学 Agent thérapeutique pour le traitement du cancer du sein comprenant un peptide inhibiteur d'interaction big3-phb2 dérivé de phb2
AU2020411439A1 (en) 2019-12-26 2022-08-04 Taiho Pharmaceutical Co., Ltd. Agent for adjuvant therapy
DE102022118517A1 (de) 2022-07-25 2024-01-25 Dennis Reitmeir Liegestützvorrichtung mit drehbaren Griffeinheiten
CN115372618A (zh) * 2022-09-19 2022-11-22 首都医科大学附属北京胸科医院 一种检测蛋白标志物水平的试剂在制备用于评估肿瘤治疗效果的诊断产品中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326067A3 (fr) 1988-01-26 1991-04-17 The Du Pont Merck Pharmaceutical Company Utilisation de cyclophyline comme agent anti-inflammatoire et immunomodulateur
EP0656788B1 (fr) * 1992-08-07 2006-10-18 Pharmexa Inc. Peptides de liaison de hla, et leurs utilisations
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein

Also Published As

Publication number Publication date
US7368107B2 (en) 2008-05-06
KR100653590B1 (ko) 2006-12-04
US7041297B1 (en) 2006-05-09
WO1999067288A1 (fr) 1999-12-29
TWI228128B (en) 2005-02-21
NZ508996A (en) 2003-09-26
DE69937294T2 (de) 2008-07-03
ATE375362T1 (de) 2007-10-15
CN1318447C (zh) 2007-05-30
KR20010053180A (ko) 2001-06-25
CA2331761A1 (fr) 1999-12-29
EP1090924B1 (fr) 2007-10-10
EP1090924A4 (fr) 2002-07-10
WO1999067288A9 (fr) 2000-03-30
DE69937294D1 (de) 2007-11-22
CN1525980A (zh) 2004-09-01
AU749544B2 (en) 2002-06-27
ID27788A (id) 2001-04-26
US20060008463A1 (en) 2006-01-12
ES2294844T3 (es) 2008-04-01
EP1090924A1 (fr) 2001-04-11
AU4392699A (en) 2000-01-10
EP1090924B8 (fr) 2007-11-21
JP4413429B2 (ja) 2010-02-10

Similar Documents

Publication Publication Date Title
EP1090924B8 (fr) Peptides d'antigenes tumoraux provenant de la cyclophiline b
EP2022800A3 (fr) Compositions utilisés dans la thérapie et le diagnostic du cancer des ovaires
WO1999038973A3 (fr) Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO1999033869A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
WO1998037093A3 (fr) Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
PL328858A1 (en) Immunogenous peptides
CA2216535A1 (fr) Inhibiteurs de proteine kinase c
EP2295453A3 (fr) Peptide de suppression de l'appétit, ses compositions et son utilisation
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2000029574A3 (fr) Genes associes a des inflammations
DE69830143D1 (en) Phosphodiesterase 8
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
EP1364657A4 (fr) Remedes contre les tumeurs affectant les organes hematopoietiques
EP0876397A4 (fr) Antigenes de rejet tumoral presentes par des molecules hla-b44 et utilisations de ces derniers
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
WO2000055194A3 (fr) Antigenes de la tuberculose et procedes de leur utilisation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110624